SLC5A2 and chronic kidney disease: In addition, sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are being adopted in treatment regimens for their kidney‐protective effects, despite the lack of specific studies in AS patients, leveraging their established benefits in chronic kidney disease (CKD) patients without diabetes to reduce the risk of progressing to kidney failure.